The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Open accessAbstract
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.Methods We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759.Findings Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease.Interpretation Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Experimental — accuracy not yet measuredIn the citing paper
“Nivolumab (BMS-936558, ONO-4538, or MDX1106, trade name Opdivo; Bristol-Myers Squibb, Princeton, NJ, USA) is a first-in-class fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) inhibitor that suppresses PD-1 activity through selectively targeting and blocking the interaction between ligands (PD-L1 and PD-L2) and PD-1 receptor [35].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [35]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,000
Aguiar, P. N., de Mello, R. A., Barreto, C. M. N., Perry, L. A., Penny‐Dimri, J. C., Tadokoro, H., & Lopes, G. D. L., Jr. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000200 · Cited by 43
Imai, Y., Hasegawa, K., Matsushita, H., Fujieda, N., Sato, S., Miyagi, E., Kakimi, K., & Fujiwara, K. (2018) · Oncology Letters · doi:10.3892/ol.2018.8101 · Cited by 43
Expert opinion on thyroid complications in immunotherapy
Illouz, F., Drui, D., Caron, P. J., & Cao, C. D. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.007 · Cited by 44
Spira, A. E., Halmos, B., & Powell, C. A. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0756up · Cited by 44
Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
Ferrara, R., Caramella, C., Besse, B., & Champiat, S. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.011 · Cited by 43
Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
Perrotta, F., Rocco, D., Vitiello, F., Palma, R. D., Guerra, G., Luca, A. D., Navani, N., & Bianco, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092258 · Cited by 43
Wang, Y., Guo, H., Feng, Z., Wang, S., Wang, Y., He, Q., Li, G., Lin, Z., Xie, X., & Lin, Z. (2019) · Molecules · doi:10.3390/molecules24203784 · Cited by 43
Ibraheim, H., Baillie, S., Samaan, M., Abu‐Sbeih, H., Wang, Y., Talley, N. J., Jones, M. P., & Powell, N. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15998 · Cited by 43
Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
Gupta, S., Gill, D. M., Poole, A., & Agarwal, N. (2017) · Cancers · doi:10.3390/cancers9020015 · Cited by 42
Leventakos, K., & Mansfield, A. S. (2016) · BioDrugs · doi:10.1007/s40259-016-0187-0 · Cited by 42
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
Ilcus, C., Bagacean, C., Tempescul, A., Popescu, C., Pârvu, A. V., Cenariu, M., Bocșan, I. C., & Zdrenghea, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133385 · Cited by 42
Immune-related adverse events by immune checkpoint inhibitors
Kadono, T. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.83 · Cited by 42
Zhao, B., Zhao, H., & Zhao, J. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0421-z · Cited by 43
Ozaki, Y., Muto, S., Takagi, H., Watanabe, M., Inoue, T., Fukuhara, M., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02446-1 · Cited by 42
Kagawa, Y., Furuta, H., Uemura, T., Watanabe, N., Shimizu, J., Horio, Y., Kuroda, H., Inaba, Y., Kodaira, T., Masago, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14605 · Cited by 42
Chen, X., Fang, L., Zhu, Y., Bao, Z., Wang, Q., Liu, R., Sun, W., Du, H., Lin, J., Yu, B., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02943-2 · Cited by 42
Wu, F., Gu, Y., Kang, B., Heskia, F., Pachot, A., Bonneville, M., Wei, P., & Liang, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1277 · Cited by 42
Montana, M., Garcia, M.-E., Ausias, N., Jeanpierre, M., Meiffren, M., Giorgi, R., Vanelle, P., & Barlési, F. (2018) · Journal of Chemotherapy · doi:10.1080/1120009x.2018.1551753 · Cited by 41
Gou, M., Qian, N., Zhang, Y., Yan, H., Si, H., Wang, Z., & Dai, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.851756 · Cited by 41
Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma
Gounant, V., Brosseau, S., Naltet, C., Opsomer, M.-A., Antoine, M., Danel, C. J., Khalil, A., Cadranel, J. L., & Zalcman, G. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.010 · Cited by 41
Self-citationOpportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge
Kostine, M., Chiche, L., Lazaro, E., Halfon, P., Charpin, C., Arniaud, D., Rétornaz, F., Blanco, P., Jourde‐Chiche, N., Richez, C., et al. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.01.004 · Cited by 41
McGinnis, G. J., & Raber, J. (2017) · Immunotherapy · doi:10.2217/imt-2017-0056 · Cited by 42
Overview of metastatic disease of the central nervous system
Nolan, C. P., & DeAngelis, L. M. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00001-3 · Cited by 42
Effect and biomarker of Nivolumab for non–small-cell lung cancer
Wang, L., Zhao, D., Qin, K., Rehman, F. U., & Zhang, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109199 · Cited by 42
Liao, H., Chen, W., Dai, Y., Richardson, J. J., Guo, J., Yuan, K., Zeng, Y., & Xie, K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00883 · Cited by 41
Mu, W., Katsoulakis, E., Whelan, C. J., Gage, K. L., Schabath, M. B., & Gillies, R. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01375-0 · Cited by 41
Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus
Kahan, S. M., & Zajac, A. J. (2019) · Viruses · doi:10.3390/v11020156 · Cited by 44
Zhao, X., Zhao, Y., Zhang, Z., Zhang, Z., Liu, L., & Zhao, X. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00956-9 · Cited by 44
Ferroptosis, autophagy, tumor and immunity
Xie, Y., Zhou, Y., Wang, J., Lijuan, D., Ren, Y., & Liu, F. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19799 · Cited by 40
Chen, M., Ma, P., Zhang, Y., Wang, D., Yu, Z., Fu, Y., Zhao, X., Wang, M., Zhuang, G., & Jing, Y. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007305 · Cited by 43
Srivastava, R., Dervillez, X., Khan, A. A., Chentoufi, A. A., Chilukuri, S., Shukr, N., Fazli, Y., Ong, N., Afifi, R. E., Osorio, N., et al. (2016) · Journal of Virology · doi:10.1128/jvi.02450-15 · Cited by 40
Tigue, N. J., Bamber, L., Andrews, J. L., Ireland, S., Hair, J. R., Carter, E. P., Sridharan, S., Jovanović, J., Rees, D. G., Springall, J. S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1280645 · Cited by 40
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy
Cooper, D. S., Meriggioli, M. N., Bonomi, P., & Malik, R. N. (2017) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-170219 · Cited by 40
IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy
Chen, J. C., Pérez‐Lorenzo, R., Saenger, Y. M., Drake, C. G., & Christiano, A. M. (2018) · Cell Systems · doi:10.1016/j.cels.2018.05.020 · Cited by 40
Kokowski, K., Stangl, S., Seier, S., Hildebrandt, M., Vaupel, P. W., & Multhoff, G. (2019) · Strahlentherapie und Onkologie · doi:10.1007/s00066-019-01434-9 · Cited by 40
Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression
Lauber, K., & Dunn, L. A. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238339 · Cited by 41
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas
Orth, M. F., Bücklein, V., Kampmann, E., Subklewe, M. S., Noeßner, E., Cidre‐Aranaz, F., Romero‐Pérez, L., Wehweck, F. S., Lindner, L. H., Issels, R. D., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02552-5 · Cited by 41
Man, J., Millican, J., Mulvey, A., Gebski, V., & Hui, R. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab012 · Cited by 40
B7 score and T cell infiltration stratify immune status in prostate cancer
Zhou, Q., Li, K., Lai, Y., Yao, K., Wang, Q., Zhan, X., Peng, S., Cai, W., Yao, W., Zang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002455 · Cited by 40
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16020340 · Cited by 44
Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
Valecha, G. K., Vennepureddy, A., Ibrahim, U., Safa, F. M., Samra, B., & Atallah, J. P. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1259574 · Cited by 39
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
Bukamur, H. S., Katz, H., Alsharedi, M. F., Alkrekshi, A., Shweihat, Y., & Munn, N. J. (2020) · Southern Medical Journal · doi:10.14423/smj.0000000000001166 · Cited by 39
Wirsching, H., & Weller, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_18 · Cited by 43
Immunotherapy for non-small cell lung cancer: current concepts and clinical trials
Mayor, M., Yang, N., Sterman, D. H., Jones, D. R., & Adusumilli, P. S. (2015) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezv371 · Cited by 38
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer
Califano, R., Kerr, K. M., Morgan, R. D., Russo, G. L., Garassino, M. C., Morgillo, F., & Rossi, A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0544-7 · Cited by 38
PD-L1 expression in large cell neuroendocrine carcinoma of the lung
Eichhorn, F., Harms, A., Warth, A., Muley, T., Winter, H., & Eichhorn, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.02.003 · Cited by 38
Matsuo, N., Azuma, K., Hattori, S., Ohtake, J., Kawahara, A., Ishii, H., Tokito, T., Yamada, K., Shibata, Y., Shimokawaji, T., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31923 · Cited by 38
Narayanapillai, S. C., Han, Y. H., Song, J. M., Kebede, M. E., Upadhyaya, P., & Kassie, F. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa059 · Cited by 39
The Role of Molecular Diagnostics in the Management of Patients with Gliomas
Wirsching, H., & Weller, M. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0430-4 · Cited by 39
Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor
Doherty, M. K., Jao, K., Shepherd, F. A., Hazrati, L., & Leighl, N. B. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000587 · Cited by 37
New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer
Verma, J., Monk, B. J., & Wolfson, A. H. (2016) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2016.05.003 · Cited by 37
Wang, C., Yu, X., & Wang, W. (2016) · Medicine · doi:10.1097/md.0000000000005539 · Cited by 37
Keller, M. D., Neppl, C., Irmak, Y., Hall, S. R. R., Schmid, R. A., Langer, R., & Berezowska, S. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.111 · Cited by 37
Ono, T., Azuma, K., Kawahara, A., Sasada, T., Hattori, S., Satô, F., Shin, B., Chitose, S.-I., Akiba, J., & Umeno, H. (2017) · Oncotarget · doi:10.18632/oncotarget.21564 · Cited by 37
Lung cancer, elderly and immune checkpoint inhibitors
Casaluce, F., Sgambato, A., Maione, P., Spagnuolo, A., & Gridelli, C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.90 · Cited by 37
Ryan, S. T., Zhang, J., Burner, D., Liss, M. A., Pittman, E. I., Muldong, M., Shabaik, A. S., Woo, J. R., Bassler, N., Cunha, J., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02370-4 · Cited by 37
Immune Checkpoint Inhibitors in Gliomas
Tan, A. C., Heimberger, A. B., & Khasraw, M. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0586-5 · Cited by 37
Prognostic role of tumour-infiltrating inflammatory cells in brain tumours
Bieńkowski, M., & Preusser, M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000251 · Cited by 37
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.008 · Cited by 37
Checkpoint inhibitors in lung cancer: latest developments and clinical potential
Schvartsman, G., Ferrarotto, R., & Massarelli, E. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016661164 · Cited by 36
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer
Genova, C., Rossi, G., Rijavec, E., Biello, F., Barletta, G., Tagliamento, M., & Grossi, F. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1313228 · Cited by 36
Ji, K., Sun, X., Liu, Y., Du, L., Wang, Y., He, N., Wang, J., Xu, C., & Liu, Q. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491730 · Cited by 36
RetractedScorer, P., Scott, M. L. J., Lawson, N. L., Ratcliffe, M., Barker, C., Rebelatto, M. C., & Walker, J. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0725-9 · Cited by 36
The actin modulator hMENA regulates GAS6‐AXL axis and pro‐tumor cancer/stromal cell cooperation
Melchionna, R., Spada, S., Modugno, F. D., D’Andrea, D., Carlo, A. D., Panetta, M., Mileo, A. M., Sperduti, I., Antoniani, B., Gallo, E., et al. (2020) · EMBO Reports · doi:10.15252/embr.202050078 · Cited by 36
Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic niche
Zhou, Y., Ke, P., Bao, X., Wu, H., Xia, Y., Zhang, Z., Zhong, H., Dai, Q., Wu, L., Wang, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30634-8 · Cited by 36
The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures
Balážová, K., Clevers, H. C., & Dost, A. F. M. (2023) · eLife · doi:10.7554/elife.82998 · Cited by 39
Genetics of triple-negative breast cancer: Implications for patient care
Afghahi, A., Telli, M. L., & Kurian, A. W. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.007 · Cited by 36
Recognizing and managing on toxicities in cancer immunotherapy
Liu, Y., Hui-fang, Y., Dong, S., Zhong, Y., & Hu, S. (2017) · Tumor Biology · doi:10.1177/1010428317694542 · Cited by 37
Verhoeven, D., Stoppelenburg, A. J., Meyer‐Wentrup, F. A. G., & Boes, M. L. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.007 · Cited by 36
Mechanisms of immunogenic cell death and immune checkpoint blockade therapy
Lin, R. A., Lin, J. K., & Lin, S. (2021) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12375 · Cited by 38
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Hirsh, V. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s104177 · Cited by 36
Takaya, K., Sonoda, M., Fuchigami, A., & Hiyoshi, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8548-16 · Cited by 35
Yasuda, Y., Urata, Y., Tohnai, R., Ito, S., Kawa, Y., Kono, Y., Hattori, Y., Tsuda, M., Sakuma, T., Negoro, S., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9230-17 · Cited by 35
Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma
Matsubara, T., Nishida, T., Higaki, Y., Tomita, R., Shimakoshi, H., Shimoda, A., Osugi, N., Sugimoto, A., Takahashi, K., Nakamatsu, D., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9851-17 · Cited by 35
Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
Bitar, S. E., Weerasinghe, C. K., El‐Charabaty, E., & Odaimi, M. (2018) · Case Reports in Oncological Medicine · doi:10.1155/2018/8408015 · Cited by 35
Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas
Qian, Z., Li, Y., Fan, X., Zhang, C., Wang, Y., Jiang, T., & Liu, X. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1434466 · Cited by 35
Gray, J. E., Chiappori, A., Williams, C. C., Tanvetyanon, T., Haura, E. B., Creelan, B., Kim, J., Boyle, T. A., Pinder-Schenck, M. C., Khalil, F. K., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2236-7 · Cited by 35
Self-citationRational combination immunotherapeutic approaches for effective cancer treatment
Phung, C. D., Nguyen, H. T., Tran, T. H., Choi, H., Yong, C. S., & Kim, J. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.020 · Cited by 35
Weaver, J. L., Zadrozny, L. M., Gabrielson, K. L., Semple, K. M., Shea, K. I., & Howard, K. E. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz045 · Cited by 35
Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway
Fenwick, C. W., Loredo-Varela, J.-L., Joo, V., Pellaton, C., Farina, A., Rajah, N., Esteves-Leuenberger, L., Decaillon, T., Suffiotti, M., Noto, A., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182359 · Cited by 37
Téglási, V., Pipek, O., Lózsa, R., Berta, K., Szüts, D., Harkó, T., Vadász, P., Rojkó, L., Döme, B., Bagó, A. G., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.05.008 · Cited by 35
Cortinovis, D. L., Chiari, R., Catino, A., Grossi, F., de Marinis, F., Sperandi, F., Piantedosi, F., Vitali, M., Parra, H. J. S., Migliorino, M. R., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13590 · Cited by 35
Jang, H.-J., Lee, H., Ramos, D., Park, I. K., Kang, C. H., Burt, B. M., & Kim, Y. T. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.10.123 · Cited by 35
Zhou, S., Xie, J., Huang, Z., Deng, L., Wu, L., Yu, J., & Meng, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.043 · Cited by 35
CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review
Khan, E. I., Shrestha, A. K., Elkhooly, M., Wilson, H. E., Ebbert, M., Srivastava, S., Wen, S., Rollins, S., & Sriwastava, S. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120089 · Cited by 35
CURRENT THERAPEUTIC STRATEGIES AND CHALLENGES IN NSCLC TREATMENT: A COMPREHENSIVE REVIEW
Mohan Kumar, M., & Sarkar, A. (2022) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-44-no-1.17411 · Cited by 35
Niu, Y., Wang, L., Zhang, X., Yu, H., Yang, C., Bai, H., Huang, K., Ren, C., Tian, G., Yin, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.927426 · Cited by 36
Deep learning in digital pathology for personalized treatment plans of cancer patients
Wen, Z., Wang, S., Yang, D. M., Xie, Y., Chen, M., Bishop, J., & Xiao, G. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.02.003 · Cited by 34
Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect
Zhu, C., Shi, Y., Li, Q., Luo, L., Li, X., Luo, Z., Lu, Y., Zhang, J., Jiang, M., Qin, B., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.022 · Cited by 34
Current state of immune checkpoints therapy for glioblastoma
Wang, H., Yang, J., Li, X., & Hai, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24729 · Cited by 36
Choudhury, N. J., & Nakamura, Y. (2015) · Cancer Science · doi:10.1111/cas.12862 · Cited by 34
The safety and efficacy of gemcitabine for the treatment of bladder cancer
Schlack, K., Boegemann, M., Steinestel, J., Schrader, A. J., & Krabbe, L. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1143777 · Cited by 34
Immune Checkpoint Inhibitors in Lung Cancer: Past, Present and Future
Seetharamu, N., Budman, D. R., & Sullivan, K. M. (2016) · Future Oncology · doi:10.2217/fon.16.20 · Cited by 34
Fang, W., Chen, Y., Sheng, J., Zhou, T., Zhang, Y., Zhan, J., Liu, L., Huang, J., Peng, P., & Zhang, L. (2017) · Journal of Cancer · doi:10.7150/jca.18729 · Cited by 34
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
Herin, H., Aspeslagh, S., Castañón, E., Dyevre, V., Marabelle, A., Varga, A., Postel-Vinay, S. C., Michot, J., Ribrag, V., Gazzah, A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.002 · Cited by 34
Therapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 34
Chen, G., Qin, Y., Fan, Q., Zhao, B., Mei, D., & Li, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3198 · Cited by 34
CAR‐Ts: new perspectives in cancer therapy
Abrantes, R., Duarte, H. O., Gomes, C., Wälchli, S., & Reis, C. A. (2022) · FEBS Letters · doi:10.1002/1873-3468.14270 · Cited by 34
Shang, H., Ding, X., Geng, R., Wu, J., Deng, W., Tong, Y., Ba, X., Zhong, Z., He, Y., Huang, Q., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c17444 · Cited by 33
Aguiar, P. N., Santoro, I. L., Tadokoro, H., Lopes, G. D. L., Jr., Filardi, B. A., Oliveira, P., Castelo‐Branco, P., Mountzios, G., & de Mello, R. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0032 · Cited by 35
Metadata
- Authors
- Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Souquet, P.-J., Baldini, E., Cappuzzo, F., Chouaid, C., Dowlati, A., Sanborn, R., Lopez-Chavez, A., Grohe, C., Huber, R. M., Harbison, C. T., Baudelet, C., Lestini, B. J., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Institut Gustave Roussy (FR)
- University of North Carolina at Chapel Hill (US)
- Roswell Park Comprehensive Cancer Center (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Azienda Ospedaliera S.Maria (IT)
- Hôpital Civil, Strasbourg (FR)
- The Ohio State University Wexner Medical Center (US)
- UC Davis Comprehensive Cancer Center (US)
- Mount Sinai Beth Israel (US)
- Lehigh Valley Hospital (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- University Hospital Cologne (DE)
- Hospices Civils de Lyon (FR)
- Ospedale di Livorno (IT)
- University Hospitals of Cleveland (US)
- Providence Portland Medical Center (US)
- German Center for Lung Research (DE)
- Princeton University (US)
- Emory University (US)
- Corresponding author
- Rizvi, Naiyer A
- ORCID
- Rizvi, Naiyer A
- Mazières, Julien
- Planchard, David
- Stinchcombe, Thomas E
- Dy, Grace K
- Antonia, Scott J
- Horn, Leora
- Mennecier, Bertrand
- Otterson, Gregory A
- Campos, Luis T
- Gandara, David R
- Levy, Benjamin P
- Nair, Suresh G
- Zalcman, Gérard
- Wolf, Jürgen
- Cappuzzo, Federico
- Chouaid, Christos
- Dowlati, Afshin
- Sanborn, Rachel
- Huber, Rudolf M
- Ramalingam, Suresh S
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 16
- Issue
- 3
- Pages
- 257-265
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5726228
- OpenAlex
- W2106511606
- Cited by
- 1,415
- References
- 36
- Citations by year
- 2026: 23 · 2025: 35 · 2024: 62 · 2023: 84 · 2022: 81 · 2021: 114 · 2020: 128 · 2019: 135 · 2018: 179 · 2017: 228 · 2016: 229 · 2015: 111
- FWCI
- 108.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- PD-1 inhibitors, lung squamous cell carcinoma, refractory lung cancer, objective response rate, treatment safety, pneumonitis, immune-related adverse events, immune checkpoint blockade, non-relapse mortality, ischemic stroke, pneumonia, fatigue, diarrhea, previously treated patients, duration of response, stable disease, time to response
- MeSH terms
- Nivolumab, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Administration Schedule, Europe, Female, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Risk Factors, Time Factors, United States, Signal Transduction, Comorbidity, Treatment Outcome, Disease Progression, Disease-Free Survival, Kaplan-Meier Estimate, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
